Molecular imaging with positron emission tomography and computed tomography (PET/CT) for selecting first-line targeted treatment in metastatic breast cancer: a cost-effectiveness study

Our aim was to evaluate the potential cost-effectiveness of PET/CT with FES and (89)Zr-trastuzumab compared to pathology to select first-line targeted treatment in metastatic breast cancer (MBC) patients with non-rapidly progressive disease. A previously published and validated model was extended an...

Descripción completa

Detalles Bibliográficos
Autores principales: Koleva-Kolarova, Rositsa G., Greuter, Marcel J.W., Feenstra, Talitha L., Vermeulen, Karin M., de Vries, Erik F.J., Parkin, David, Buskens, Erik, de Bock, Geertruida H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5929430/
https://www.ncbi.nlm.nih.gov/pubmed/29731987
http://dx.doi.org/10.18632/oncotarget.24869

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5929430/
https://www.ncbi.nlm.nih.gov/pubmed/29731987
http://dx.doi.org/10.18632/oncotarget.24869

Ejemplares similares